FDA panel rejects testosterone patch for women on safety grounds

A panel of advisers to the US Food and Drug Administration last week unanimously rejected an experimental testosterone patch as a treatment for women with sexual difficulties. Procter & Gamble, global manufacturer of household products, wants to market the patch to women who have become menopausal after ovarian surgery, are currently taking oestrogen, and are said to have a controversial condition—“hypoactive sexual desire disorder.” The FDA had granted Procter & Gamble a fast track review of the testosterone patch, but the committee's unanimous …